Delving into the Latest Updates on Cabozantinib (s)-Malate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

cabozantinib, Cabozantinib Malate, Cabozantinib s-malate (USAN)

+ [9]

Target

AXL x RET x ROS1 x TYRO3 x Tie-2 x TrkB x VEGFR1 x VEGFR2 x VEGFR3 x c-Kit x c-Met

Action

inhibitors, antagonists

Mechanism

AXL inhibitors(AXL receptor tyrosine kinase inhibitors), RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors), ROS1 inhibitors(Proto-oncogene tyrosine-protein kinase ROS inhibitors)

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [11]

Active Indication

Extra-pancreatic neuroendocrine tumorNeuroendocrine tumor of pancreasDifferentiated Thyroid Gland Carcinoma+ [191]

Inactive Indication

Advanced Bile Duct CarcinomaAdvanced breast cancerCarcinoma of extrahepatic bile duct+ [40]

Originator Organization

Exelixis, Inc.

Active Organization

Exelixis, Inc.

National Cancer Institute

Ipsen SA

+ [19]

Inactive Organization

University of Washington

Jiangsu Hansoh Pharmaceutical Co., Ltd.

EMD Serono, Inc.

License Organization

Ipsen SA

Takeda Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd.

+ [7]

Drug Highest PhaseApproved

First Approval Date

United States (29 Nov 2012),

Thyroid Cancer, Medullary

RegulationPriority Review (United States), Breakthrough Therapy (United States), Fast Track (United States), Orphan Drug (United States)

Login to view timeline

Structure/Sequence

Molecular FormulaC32H30FN3O10

InChIKeyHFCFMRYTXDINDK-WNQIDUERSA-N

CAS Registry1140909-48-3

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating β-catenin-mutated metastatic hepatocellular carcinoma.

Start Date10 Feb 2026

Sponsor / Collaborator

National Cancer Institute

NCT06900595

/ Not yet recruitingPhase 2IIT

A Phase II Study of Cabozantinib in Combination With Cemiplimab (Cabo-Cemiplimab) Versus Cabozantinib Alone in Adolescents and Adults With Advanced Adrenocortical Cancer

This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by surgery (unresectable) or that has come back after a period of improvement (recurrent) or that has spread from where it first started (primary site) to other places in the body (metastatic). Cabozantinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving cabozantinib with cemiplimab may kill more tumor cells in patients with locally advanced unresectable or recurrent/metastatic adrenocortical cancer.

Start Date31 Jul 2025

Sponsor / Collaborator

National Cancer Institute

NCT06502171

/ Not yet recruitingPhase 1IIT

A Phase 1/1b/2 Study of Cabozantinib in Combination With Selumetinib for Plexiform Neurofibroma in Adults and Adolescents With Neurofibromatosis Type 1

Based on the clinical activity of both selumetinib and cabozantinib as monotherapies in clinical trials, the demonstrated activity of these agents in reduced doses in preclinical studies, and the non-overlapping toxicity profiles, the study will assess the tolerability and efficacy of selumetinib and cabozantinib in combination in participants with NF1 ≥16 years old with progressive and/or symptomatic PN in a phase 1/1b/2 clinical trial.
Trial Design Phase 1 This will be an open label, dose escalation phase. Dose level escalation will be determined by a rolling six design. In this design, up to 6 participants can be enrolled at a given dose level and then evaluated for dose limiting toxicity (DLT) within the DLT window. The DLT window is defined as 16 weeks in this study based on the long half-life of cabozantinib and the desire to have maximum confidence about long-term tolerability of the combination prior to proceeding to the next dose level.
Phase 1b Once the recommended phase 2 dose has been determined in phase 1, an expanded cohort of 12 participants will be enrolled in phase 1b portion of the study.
Phase 2 This will be an open label, single-arm phase using the recommended phase 2 dose.

Start Date01 Jul 2025

Sponsor / Collaborator

The University of Alabama at Birmingham

[+2]

100 Clinical Results associated with Cabozantinib (s)-Malate

Login to view more data

100 Translational Medicine associated with Cabozantinib (s)-Malate

Login to view more data

100 Patents (Medical) associated with Cabozantinib (s)-Malate

Login to view more data

2,701

Literatures (Medical) associated with Cabozantinib (s)-Malate

01 Sep 2025·EUROPEAN JOURNAL OF PHARMACOLOGY

Investigating the ‘RT-PK’ phenomenon: Effects of X-ray radiation on cabozantinib metabolism

Article

Author: Zhang, Junxia ; Fan, Huirong ; Liang, Bohan ; Ma, Jiaojiao ; Shang, Yan ; Teng, Yunhua ; Li, Yanjie ; Wang, Lingmei ; Dong, Shiqi ; Zhu, Huazhen

BACKGROUND AND PURPOSE:

This study investigated whether the "RT-PK" phenomenon, referring to radiation therapy's effects on the pharmacokinetics of chemotherapeutic agents, occurs with cabozantinib, a multikinase inhibitor, after radiotherapy and investigated the underlying mechanisms.

METHOD:

A quantitative liquid chromatography-tandem mass spectrometry method was developed for cabozantinib. Sprague-Dawley (SD) rats were irradiated with X-rays, and changes in cabozantinib distribution and concentration in the blood and excreta were monitored. The RT-PK phenomenon was confirmed, and further studies examined liver injury and alterations in primary metabolic enzymes in rats and HepG2 cells using hematoxylin and eosin staining, flow cytometry, Western blot, quantitative reverse transcription polymerase chain reaction, and serum biochemical analysis. The mRNA expression of IL6/STAT3 and PXR was also determined.

RESULTS:

X-ray exposure increased the area under the drug-time curve (AUC_0-t) of cabozantinib by 3.6-fold, and excretion of the drug in the feces was 73 % lower in irradiated rats. Hematoxylin and eosin staining showed hepatocyte and interstitial edema, and serum Alanine transaminase and aspartate transaminase contents were decreased. Radiation induced redox imbalance, increased reactive oxygen species and apoptotic markers, and reduced superoxide dismutase and GSH/GSSG contents. As indicated by western blotting and RT-qPCR, the activation of the IL-6/STAT3 pathway reduced PXR expression, leading to decreased levels of CYP450 3A4, the key enzyme that metabolizes cabozantinib.

CONCLUSIONS:

Radiation increased reactive oxygen species, activated the IL-6/STAT3 pathway, and inhibited PXR, thereby reducing CYP450 3A4 expression. These changes led to altered cabozantinib metabolism and the "RT-PK" phenomenon.

01 Aug 2025·Clinical Genitourinary Cancer

Cabozantinib in the First-Line Treatment of Patients With Metastatic Renal Cell Carcinoma, Real-World Data From the Czech Republic and Poland: ICARO-RC Project

Article

Author: Lacek, Michal ; Poprach, Alexandr ; Domański, Piotr ; Bezděková, Monika ; Kopecky, Jindrich ; Richter, Igor ; Kolaríková, Eva ; Sikora-Kupis, Bożena ; Pinto, Alvaro ; Studentova, Hana ; Koloušková, Ivana ; Buchler, Tomas ; Kucharz, Jakub ; Fiala, Ondrej ; Darewicz, Marta

INTRODUCTION:

The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically in the last few years, with different options being available, and with no data comparing these new systemic therapies. Therefore, the value of real-world outcomes (RWO) becomes of great interest to understand the effectiveness of these treatments. Here we analyze the outcome of metastatic RCC patients treated with first-line cabozantinib in a retrospective cohort from the Czech Republic and Poland METHODS: Patients with metastatic RCC treated with first-line cabozantinib in the Czech Republic and Poland were included in a retrospective fashion. Data were collected regarding progression-free survival (PFS), overall survival (OS), response rate and toxicity, with a focus in several subgroups of interest.

RESULTS:

We identified 146 patients, the majority of them (80.8%) with clear cell RCC (ccRCC). The median OS was 14.7 months, and the median PFS 8.2 months, with a response rate of 30.3%. CTCAE v3.0 grade 3+4 toxicity was presented in 34.2% of patients. The efficacy of Cabozantinib was maintained regardless of histologic subtype and the presence of sarcomatoid component, although PFS and OS data were numerically better for nonclear cell RCC. Bone and liver metastases were confirmed as independent factor for poor survival in the multivariate analysis.

CONCLUSIONS:

In our series, Cabozantinib demonstrated its activity in RCC patients in a RWO setting. Our data can be considered comparable with what has been seen in randomised clinical trials, considering the inherent bias present in RWO studies.

01 Jul 2025·COMPUTERS IN BIOLOGY AND MEDICINE

Computer-aided drug discovery of a dual-target inhibitor for ovarian cancer: therapeutic intervention targeting CDK1/TTK signaling pathway and structural insights in the NCI-60

Article

Author: Chen, Lung-Ching ; Tang, Sung-Ling ; Wang, Hong-Jaan ; Hsu, Han-Lin ; Wu, Alexander T H ; Ansar, Muhamad ; Kuo, Yu-Cheng ; Lee, Shih-Yu ; Huang, Sheng-Liang ; Sumitra, Maryam Rachmawati ; Lawal, Bashir ; Huang, Hsu-Shan

Ovarian cancer remains the third most prevalent and deadliest gynecologic malignancy worldwide, with most patients eventually developing resistance to platinum-based chemotherapy. This highlights a critical unmet need for innovative multitargeted therapies to address current treatment challenges. In this study, we identified 35 differentially expressed genes (DEGs) through integrated analysis of four GEO ovarian cancer datasets, with validation using TCGA data. Gene Ontology (GO) and KEGG enrichment analyses highlighted key tumor-associated pathways, and protein-protein interaction (PPI) network modeling prioritized CDK1 and TTK as high-value therapeutic targets. We evaluated the association between molecular genomic features and drug responses across the NCI-60 ovarian cancer cell line panel (IGROV1, OVCAR-3, OVCAR-4, OVCAR-5, OVCAR-8, NCI/ADR-RES, and SK-OV-3), using a series of salicylanilide-derived compounds and four FDA-approved drugs (cabozantinib, paclitaxel, rapamycin, and niclosamide) from the NCI Developmental Therapeutics Program (DTP). Among these, NSC765690 (MCC22) emerged as the most promising candidate. It demonstrated potent antiproliferative activity, high target selectivity, and strong binding affinity to both CDK1 and TTK. Multi-omics integration, combined with AI-driven network modeling, further elucidated NSC765690's mechanism of action and its relevance to ovarian cancer pathogenesis. Additionally, ADMET and pharmacokinetic profiling confirmed its favorable drug-like properties and low predicted toxicity. Collectively, these findings establish NSC765690 as a potent dual-target inhibitor and exemplify a rational, data-driven drug discovery pipeline for overcoming chemotherapy resistance in ovarian cancer.

487

News (Medical) associated with Cabozantinib (s)-Malate

26 Jun 2025

·pmlive.com

Ipsen receives CHMP recommendation for Cabometyx in neuroendocrine tumours

Ipsen has announced that its Exelixis-partnered Cabometyx (cabozantinib) has been recommended by the European Medicines Agency’s human medicines committee to treat advanced neuroendocrine tumours (NETs). The Committee for Medicinal Products for Human Use (CHMP) has recommended that the drug be authorised to treat unresectable or metastatic, well-differentiated extra-pancreatic and pancreatic NETs in adults who have progressed following at least one prior systemic therapy other than somatostatin analogues. The number of people newly diagnosed with NETs, tumours that arise from the neuroendocrine cells found throughout the body, is believed to be rising. Most NETs develop slowly over a number of years and patients often need multiple lines of therapy as the disease progresses. Cabometyx is designed to block the action of multiple receptor tyrosine kinases, which can be found in certain receptors in cancer cells and help to send growth signals. The drug is already approved in the EU to treat certain cases of renal cell carcinoma, thyroid carcinoma and hepatocellular carcinoma. The CHMP’s positive opinion was based on results from the phase 3 CABINET trial, in which Cabometyx demonstrated continued improvement in the primary endpoint of progression-free survival (PFS). Among patients with pancreatic NETs, median PFS was 13.8 months for Cabometyx versus 4.4 months for placebo after a median follow-up of 13.8 months. For those with extra-pancreatic NETs, median PFS was 8.4 months and 3.9 months for Cabometyx and placebo, respectively, at a median follow-up of 10.2 months. The European Commission (EC) will now review the CHMP’s recommendation as it makes a final decision on Cabometyx in this indication. Christelle Huguet, executive vice president and head of research and development at Ipsen, said: “The significant efficacy data demonstrated in the CABINET phase 3 trial has provided the opportunity to reframe conversations on care approaches for people living with advanced pancreatic and extra-pancreatic NETs. “[The] positive CHMP opinion confirms the potential to translate this data into meaningful benefits for patients and we look forward to receiving the final decision from the EC.” Exelixis holds exclusive rights to develop and commercialise Cabometyx in the US, and has granted Ipsen exclusive rights to the drug outside of the US and Japan, and exclusive rights to Takeda in Japan.

Clinical ResultPhase 3License out/inDrug Approval

23 Jun 2025

·www.fiercebiotech.com

Exelixis\' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher

Investors sent Exelixis’ share price up 12% to about $45 on Monday.\n A combination featuring Exelixis’ experimental drug zanzalintinib has beaten Bayer’s gastrointestinal cancer med Stivarga in a phase 3 trial. The overall survival win moves Exelixis a step closer to its ambition of turning the oral tyrosine kinase inhibitor into a $5 billion-a-year product.Exelixis is developing zanzalintinib as the successor to its flagship oncology medicine Cabometyx. By improving attributes including pharmacokinetic half-life, the company has designed a molecule that it believes can win approval in a range of diseases and blast past Cabometyx’s peak sales. The phase 3 colorectal cancer trial was a key early proving ground for zanzalintinib.Investigators randomized 901 patients to receive Stivarga or zanzalintinib in combination with Roche’s checkpoint inhibitor Tecentriq. Overall survival in previously treated non-microsatellite instability-high metastatic colorectal cancer was significantly longer on the combination than on Stivarga.William Blair analysts said in a note to investors that the hit on the trial’s co-primary endpoint ensures a “meaningful commercial opportunity for the budding franchise.” The patient population covered by the endpoint represents the largest commercial opportunity open to zanzalintinib, according to analysts, who estimated risk-adjusted U.S. peak sales of $875 million. The analysts will be looking out for relative and absolute risk reduction when the full results are shared, because “these metrics could help us ascertain the clinical meaningfulness of the survival benefit.” But the available results are positive, leading investors to send Exelixis’ share price up 12% to about $45 on Monday.Exelixis will, however, need to rack up more clinical wins to deliver its major vision for zanzalintinib. The biotech expects GI cancers, including colorectal tumors, to account for 45% of the $5 billion in sales it hopes to generate in 2033. GI cancers accounted for 10% of Cabometyx sales last year, making the indications central to Exelixis’ ambitions to improve on the $1.8 billion generated by its current product.The biotech’s pursuit of the phase 3 colorectal cancer population could put it in competition with drugs including Amgen’s Lumakras, Bayer’s Stivarga, Taiho Oncology’s Lonsurf and Takeda’s Fruzaqla.

$Exelixis\' blockbuster hopeful beats Bayer drug in pivotal cancer trial, sending stock higher$

Phase 3Clinical ResultADC

23 Jun 2025

·endpoints.news

Exelixis' positive Phase 3 colorectal cancer data boost stock

Shares $EXEL of Exelixis jumped after the company reported positive Phase 3 data from one of its cancer studies. Exelixis said Monday that a combination of its oral TKI inhibitor zanzalintinib and Roche’s Tecentriq achieved a statistically significant improvement in overall survival for certain patients with metastatic colorectal cancer. Patients were randomized to take the combo therapy or Bayer’s Stivarga, which is the standard of care for this indication. Stivarga was first approved in 2012. Exelixis did not report specific figures such as overall survival rates between the two study arms or the endpoint’s p-value, but it plans to reveal the full study results at an upcoming medical meeting. The company’s stock price was up more than 20% in early trading on Monday. Much of the focus on Exelixis has been on Cabometyx, which has racked up six approvals since 2016 in cancers of the kidney, liver and thyroid. Zanzalintinib is its most advanced pipeline program, and investors are hopeful for a near-term launch. TD Cowen analyst Yaron Werber wrote in a note on Monday that approval in metastatic colorectal cancer could come next year, and he estimates that it’s a $500 million market. He also thinks zanzalintinib could ultimately produce annual peak sales of $1.5 billion if it gets approved to treat neuroendocrine tumors in addition to head and neck and renal cell carcinoma. In the readout on Monday, Exelixis said zanzalintinib succeeded in a group of patients previously treated for non-microsatellite instability colorectal cancer. Overall survival represented one of the Phase 3 study’s co-primary endpoints. The other primary endpoint is OS in patients without liver metastases. The company is also measuring progression-free survival, objective response rate and duration of response for secondary endpoints. Rates will be measured in both the full trial population and the subgroup of patients without liver metastases.

Clinical ResultPhase 3Drug Approval

100 Deals associated with Cabozantinib (s)-Malate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10095	Cabozantinib (s)-Malate	L01XE26	DB08875

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Extra-pancreatic neuroendocrine tumor	United States	Exelixis, Inc.	26 Mar 2025
Neuroendocrine tumor of pancreas	United States	Exelixis, Inc.	26 Mar 2025
Differentiated Thyroid Gland Carcinoma	South Korea	Ipsen Ltd.	26 Sep 2017
Renal Cell Carcinoma	South Korea	Ipsen Ltd.	26 Sep 2017
Hepatocellular Carcinoma	European Union	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Iceland	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Liechtenstein	Ipsen Pharma SAS	09 Sep 2016
Hepatocellular Carcinoma	Norway	Ipsen Pharma SAS	09 Sep 2016
Advanced Renal Cell Carcinoma	United States	Exelixis, Inc.	25 Apr 2016
Thyroid Cancer, Medullary	United States	Exelixis, Inc.	29 Nov 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	NDA/BLA	China	Jiangsu Hansoh Pharmaceutical Co., Ltd.	28 Sep 2020
Refractory Differentiated Thyroid Gland Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	22 Aug 2024
Refractory Thyroid Gland Carcinoma	Phase 3	United States	ECOG-ACRIN Medical Research Foundation, Inc.	22 Aug 2024
Metastatic osteosarcoma	Phase 3	United States	National Cancer Institute	03 Mar 2023
Advanced Urothelial Carcinoma	Phase 3	United States	National Cancer Institute	03 Jun 2022
Advanced Urothelial Carcinoma	Phase 3	Canada	National Cancer Institute	03 Jun 2022
Bladder Cancer	Phase 3	United States	National Cancer Institute	03 Jun 2022
Bladder Cancer	Phase 3	Canada	National Cancer Institute	03 Jun 2022
Metastatic Urethral Urothelial Carcinoma	Phase 3	United States	National Cancer Institute	03 Jun 2022
Metastatic Urethral Urothelial Carcinoma	Phase 3	Canada	National Cancer Institute	03 Jun 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05536141 (ARC-20, PipelineReview) Manual	Phase 1	Renal Cell Carcinoma	42	Casdatifan 100mg QD + Cabozantinib 60mg QD	wncnplcfbi(ybsekzzgch) = ovttzhgkfy vshalcroyl (yvcywbkrad, 26 - 67) View more	Positive	02 Jun 2025
NCT05536141 (ARC-20, ASCO2025) Manual	Phase 1	Renal Cell Carcinoma	27	Casdatifan 100 mg + Cabozantinib 60 mg	elixtqpbvu(zorhpkfuhy) = qruaudvfto lcdqzlrmkq (hcmctfvhks ) View more	Positive	30 May 2025
NCT01639508 (phase II study of cabozantinib in patients with MET-altered lung cancers, ASCO2025)	Phase 2	Lung Cancer MET exon 14 alterations \| MET amplification	28	Cabozantinib 60 mg daily	ovsxsgthmu(veidlzqjzs) = xpkxirnkmo rjhrtgcpof (eakbwoknyo, 8.9 - 39.1) View more	Positive	30 May 2025
CABONEN (ASCO2025)	Phase 2	Neuroendocrine Tumors Ki67	45	Cabozantinib	klndwsncaa(wxzgyobbsf) = bgdzggfbea guemqdvjxx (wsjqjysppc ) View more	Positive	30 May 2025
NCT04413123 (phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh), ASCO2025)	Phase 2	Advanced Renal Cell Carcinoma	20	Cabozantinib 20 mg/d + Nivolumab 3 mg/kg + Ipilimumab 1 mg/kg	qelvcshjps(exiyylvwhl) = rhdybersws kcjvgvswkg (rcsgzcyzwy, 13 - 41) View more	Positive	30 May 2025
NCT04338269 (CONTACT-03, ASCO2025)	Phase 3	Advanced Renal Cell Carcinoma Second line	522	Cabozantinib (cabo)	drgugarqwk(jpgvqrjktp) = elgueuchfn qmxnsecqkh (sxrpoozbid ) View more	Positive	30 May 2025
NCT04338269 (CONTACT-03, ASCO2025)	Phase 3	Advanced Renal Cell Carcinoma Second line	522	Cabozantinib (cabo) + Atezolizumab (atezo)	drgugarqwk(jpgvqrjktp) = gbmtnpjgxf qmxnsecqkh (sxrpoozbid ) View more	Positive	30 May 2025
ASCO2025	Not Applicable	Advanced Hepatocellular Carcinoma Second line	552	Lenvatinib	dxfvgamxcw(bliomnzdiv) = wyfretkpqc hbcyjqvaae (qdishfwxkp )	Negative	30 May 2025
ASCO2025	Not Applicable	Advanced Hepatocellular Carcinoma Second line	552	Cabozantinib	dxfvgamxcw(bliomnzdiv) = cdrjqhfdev hbcyjqvaae (qdishfwxkp )	Negative	30 May 2025
NCT01441947 (CTgov)	Phase 2	Hormone receptor positive breast cancer	68	Cabozantinib (Cabozantinib)	bgdcrqojxf = kjwotldhcy favuaszmfh (txpcqgijzt, hagcirpuyk - tcirgdfqma) View more	-	25 May 2025
NCT01441947 (CTgov)	Phase 2	Hormone receptor positive breast cancer	68	fulvestrant+Cabozantinib (Cabozantinib Plus Fulvestrant)	lmsjfuxwvd(drkifrcpkv) = kwclgcvfxg iguttxjfgs (vzqymispli, ebjrsordbo - hcawphwhvo) View more	-	25 May 2025
NCT03170960 (COSMIC-021, Pubmed \| J Clin Oncol)	Phase 1	Metastatic urothelial carcinoma First line \| First line	121	Cabozantinib 40 mg + Atezolizumab 1,200 mg	ybucisokll(gilewgivon) = thhcevyryk edhugsbfxo (ogugdyrwhs, 15 - 49) View more	Positive	10 May 2025
NCT06026410 (FIT-001, AACR2025)	Phase 1	Renal Cell Carcinoma	-	Farnesyl transferase inhibitor KO-2806	xlbrxgebqk(pdksnfxswz) = lwmfjvftkf gwvzjjpfnp (qfasqdgcvq )	Positive	28 Apr 2025
NCT06026410 (FIT-001, AACR2025)	Phase 1	Renal Cell Carcinoma	-	Cabozantinib	sgditlpaye(okenrqjucm) = cpqsvamcpq jjfklifmkf (rwjgoztghr )	Positive	28 Apr 2025